Tag Archives: Diabetes

Novo and Echosens Partnership to Increase NASH Awareness; GlucoTrack to Initiate First In-human Clinical Study for GlucoTrack 2.0

Two cardiometabolic-related news items have been observed: Novo Nordisk and Echosens announced a partnership to increase awareness and advance early diagnosis of NASH; and GlucoTrack, formerly known as Integrity Applications, provided development updates on its Gen 2 non-invasive glucose monitor (press release). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Illinois Expands Insurance Coverage to Include CGMs; Adocia Announces Positive Top-line Results from Ph2 M1Pram Trial; June 20-23 CHMP Agenda

Three cardiometabolic-related news items have been observed; new Illinois law requires insurance and managed health plans to expand insurance coverage to include CGMs for people with T1DM and T2DM (view article); Adocia announced positive top-line results from its Ph2 trial (view CT.gov record) comparing M1Pram to Humalog in T1DM; and the CHMP agenda for this month’s meeting (June 20-23) has been released. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Senseonics Eversense E3 CGM Receives CE Mark; Tandem Appoints Two New Members to Board of Directors; Akero Announces Financing Transactions with Pfizer and Hercules Capital

Three cardiometabolic-related news items have been observed: Senseonics announced it has received CE Mark for the next-generation Eversense E3 CGM system; Tandem announced the appointment of two new directors to its board; and Akero Therapeutics announced two financing transactions with Pfizer and Hercules Capital. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Updated Abbott vs. Dexcom CGM Tale-of-the-tape Analysis

The CGM market continues to be dynamic, most recently with Abbott’s Libre 3 receiving FDA approval (previous FENIX insight) and Dexcom’s G7 approval right around the corner. Both companies represented well at ATTD and ADA, and momentum should continue into EASD (Sept 19-23). With Dexcom’s G7 US approval anticipated soon, FENIX updated its tale-of-the-tape comparative analysis between Abbott’s Libre 2 and 3 vs. Dexcom’s G6 and G7 CGM systems.

This content is for Read Less members only.
Register

Already a member? Log in here

Thoughts after ATTD and ADA 2022

Now that we’re on the other side of ADA 2022, FENIX provides provocative thoughts below on various items in the cardiometabolic space. Included are thoughts about Lilly, Novo, Sanofi, Dexcom, Abbott, Medtronic, Bigfoot, and Beta Bionics.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly ADA 2022 Investor Call

Lilly hosted an ADA 2022 investor event in which the company covered tirzepatide SURMOUNT-1 trial results, tri-agonist GGG, oral incretins, and a summary slide of Lilly’s CVRM R&D portfolio (view slides). Prior to the call, during the morning session at ADA 2022, it was publicly disclosed that Lilly will be conducting SURPASS-EARLY, thought to be a long-term trial investigating the durability of glycemic control in T2DM for tirzepatide vs. placebo in addition to SOC. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2022 Key Press Releases (June 5-6)

On the third and fourth days of ADA 2022, seven cardiometabolic-related news items were observed from Abbott, Bigfoot, BI/Lilly, Intercept, Amarin, Vertex, and Sernova. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

Novo Hosts ADA 2022 Investor Event

Novo Nordisk hosted its 2022 ADA investor event primarily focusing on its obesity and QW insulin portfolio (view slides). Of note, management emphasized GLP-1RA class growth, SELECT’s upcoming interim analysis, plans to study even higher doses of semaglutide in T2DM, and the feasibility of a cagrisema H2H trial vs. tirzepatide. Below are highlights and insights from the call.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2022 Key Press Releases (June 4)

On the second day of ADA 2022, six cardiometabolic-related news items were observed from Lilly, ADA, Insulet, vTv Therapeutics, and One Drop. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2022 Key Press Releases (June 3)

On the first day of ADA 2022, four cardiometabolic-related news items were observed from Novo, Abbott, Dario, and Zealand. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here